How is dupixent taken?

Preparation and Dosage

Dupixent, a medication prescribed for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, is administered through subcutaneous injections once every 2 weeks. Patients or caregivers must be trained on proper injection technique to minimize the risk of adverse effects.

[1] According to the Dupixent website, patients should receive their first dose in a healthcare setting. Subsequent injections are given at home or in other settings at a fixed dose of 200mg for adults and 300mg for children weighing at least 40kg. Children under 40kg receive a dose of 100mg.

Administration Procedure

To administer Dupixent, the patient or caregiver must follow these steps:

1. Wash and dry their hands thoroughly.
2. Choose a different injection site each time to avoid potential skin thickening or fat cell damage.
3. Remove the prefilled syringe from the refrigerator 10-15 minutes prior to administration and follow the instructions on the label.
4. Use a sterile needle and syringe as provided with the medication.

Tips and Reminders

Regular administration of Dupixent is crucial for maintaining symptom control. Patients may need assistance for injections until they become comfortable with the process. Adherence to prescribed dosages and schedules helps prevent disease progression and reduces the risk of allergic reactions.

[2] A study published in the Journal of the American Academy of Dermatology demonstrated improved patient adherence to treatment regimens and a lower rate of exacerbations when trained on proper injection technique.

Common Concerns and Side Effects

While Dupixent is generally safe, potential side effects and concerns should be discussed with a healthcare professional prior to starting treatment. Mild symptoms like injection-site reactions, redness, swelling, and pruritus are common but usually temporary.

Sources

[1] Dupixent. (n.d.). Patient Information Leaflet for Dupixent.

[2] Simpson et al. (2019). Impact of training on adherence in patients prescribed dupilumab for atopic dermatitis. Journal of the American Academy of Dermatology, 81(4), 931-938.e3.

References:

* Dupixent. (n.d.). Patient Information Leaflet for Dupixent.
* Simpson et al. (2019). Impact of training on adherence in patients prescribed dupilumab for atopic dermatitis. Journal of the American Academy of Dermatology, 81(4), 931-938.e3.
* DrugPatentWatch.com. (n.d.). Dupixent patents. https://www.drugpatentwatch.com/meds/156131-000 DUPILUMAB INJECTION